* Fortress Biotech Inc reported a quarterly adjusted loss of 76 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -94 cents. The mean expectation of three analysts for the quarter was for a loss of 59 cents per share. Wall Street expected results to range from -92 cents to -27 cents per share.
* Revenue fell 57.9% to $14.63 million from a year ago; analysts expected $32.22 million.
* Fortress Biotech Inc's reported EPS for the quarter was a loss of 76 cents.
* The company reported a quarterly loss of $12.87 million.
* Fortress Biotech Inc shares had risen by 8.7% this quarter and lost 47.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 47.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Fortress Biotech Inc is $13.00 This summary was machine generated from LSEG data November 15 at 02:10 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.59 -0.76 Missed
Jun. 30 2024 -1.22 -0.73 Beat
Mar. 31 2024 -1.73 -1.03 Beat
Dec. 31 2023 -1.97 -1.28 Beat
Comments